SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
-2.7%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$849M
AUM Growth
+$849M
(-5.5%)
Cap. Flow
-$6.27M
Cap. Flow
% of AUM
-0.74%
Top 10 Holdings %
Top 10 Hldgs %
99.98%
Holding
12
New
–
Increased
3
Reduced
–
Closed
1
Top Buys
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$13M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$6.21M |
| 3 |
Mersana Therapeutics
MRSN
|
$4.97M |
Top Sells
| 1 |
AbbVie
ABBV
|
$30.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$19.4B
| $182M | 21.47% | 643,000 | – | – |
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $132M | 15.58% | 928,100 | – | – |
|
3
Alkermes
ALKS
$4.78B
| $130M | 15.26% | 7,825,000 | – | – |
|
4
Ironwood Pharmaceuticals
IRWD
$214M
| $126M | 14.87% | 14,040,000 | – | – |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $91.3M | 10.75% | 797,740 +54,240 | +7% | +$6.21M |
|
6
Innoviva
INVA
$1.29B
| $67M | 7.89% | 6,414,000 | – | – |
|
|
7
Mersana Therapeutics
MRSN
$36.5M
| $52.8M | 6.22% | 2,837,000 +267,000 | +10% | +$4.97M |
|
|
ICPT
8
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $49.8M | 5.86% | 1,201,000 | – | – |
|
|
9
BioCryst Pharmaceuticals
BCRX
$1.74B
| $16.7M | 1.97% | 4,861,000 +3,786,000 | +352% | +$13M |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $951K | 0.11% | 1,851,851 | – | – |
|
|
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $166K | 0.02% | 1,000 | – | – |
|
|
12
AbbVie
ABBV
$372B
| – | – | -310,150 | Closed | -$30.5M |
|